Milano, Italy, February 02, 2012 --(PR.com
)-- Bio3 Research S.r.l. (Milan/Italy) is pleased to announce that it has completed its acquisition of the full ownership of all the patents in its portfolio concerning HMGB1 (High Mobility Group Box 1).
HMGB1 patents have been granted to Bio3 Research in the USA, Europe, Japan, Australia, Mexico, PRC, and Italy. Other patents are still pending (at a very final stage) in the USA (two divisionals), in Canada, and in the PRC (one divisional application).
With this acquisition, the company has gained a dominant position in the field of HMGB1 since its patent portfolio covers the use of HMGB1 antagonists (e.g. antagonists of any nature, antibodies, antibody fragments, four-way DNA, HMGB1 fragments such as Box-A and its variants, etc.) for the treatment of vascular diseases (including restenosis, arterial stenosis, and atherosclerotic plaque progression), and the use of the HMGB1 protein and its fragments (such as Box-A and its variants, etc.) in Connective Tissue Remodelling (e.g. healing of wounds, burns, and bedsores, cartilage repair, bone matrix reconstitution, ligament and tendon reconstitution, rheumatoid arthritis, lupus erythematosus, psoriasis, atopic dermatitis, etc.).